Formalin-fixed, paraffin embedded tissue block, or ten unstained 4 micron-thick sections on non-plus slides and one H&E stained section

One tumor-containing formalin-fixed paraffin embedded tissue block or 10 unstained 4 micron-thick sections on non-plus slides and one H&E stained section from one tumor-containing FFPET block or any or all unstained or stained slides from tumor-containing fine needle aspirate cytologic preparations.

Specimens that have been decalcified will not be accepted.

10-14 days

Fusion or mutation not detected

Tissue sections are reviewed by a pathologist. RNA is isolated from the selected area of the sample. Anchored multiplex PCR for targeted next-generation sequencing is performed. The sequenced sample is a reverse transcription PCR-amplified fragment library in which each sample is uniquely identified by ligation of a short oligonucleotide barcode. The resultant sequence identifies the exons of the fusion transcript arising from the specific gene target and the partner gene.

The panel targets gene rearrangements of these gene targets: AKT1, ALK, AXL, BRAF, CCND1, EGFR (vIII), FGFR1, FGFR2, FGFR3, MET (exon 14 skip), NRG1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS, and THADA.

Massively parallel next generation sequencing on RNA

81445